Drug Type Antibody drug conjugate (ADC) |
Synonyms anti-BCMA-ADC, Belamaf, Belantamab mafodotin (genetical recombination) (JAN) + [11] |
Target |
Action inhibitors |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (05 Aug 2020), |
RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), PRIME (European Union), Breakthrough Therapy (China), Priority Review (China) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11595 | Belantamab mafodotin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Recurrent Multiple Myeloma | Japan | 19 May 2025 | |
Multiple Myeloma | United States | 05 Aug 2020 | |
Refractory Multiple Myeloma | United States | 05 Aug 2020 | |
Relapse multiple myeloma | United States | 05 Aug 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Residual Neoplasm | Phase 2 | United States | 19 Aug 2024 | |
Bone Marrow Neoplasms | Phase 2 | United States | 21 Jul 2022 | |
Plasma Cell Leukemia | Phase 2 | United States | 21 Jul 2022 | |
Corneal Diseases | Phase 2 | Greece | 13 Apr 2022 | |
BCMA Positive Multiple Myeloma | Phase 2 | United States | 21 Feb 2022 | |
ALK positive large B-cell lymphoma | Phase 2 | United States | 01 Jul 2021 | |
Plasmablastic Lymphoma | Phase 2 | United States | 01 Jul 2021 | |
Immunoglobulin Light-Chain Amyloidosis | Phase 2 | France | 26 Feb 2021 | |
Immunoglobulin Light-Chain Amyloidosis | Phase 2 | Germany | 26 Feb 2021 | |
Immunoglobulin Light-Chain Amyloidosis | Phase 2 | Greece | 26 Feb 2021 |
Phase 3 | 21 | (Belantamab Mafodotin+Pomalidomide+Dexamethasone) | enafakxfwa(lyhwxbpnbk) = kzkgkgajib njxzwredge (kncpdpetyi, yumsyqsggw - mdfpxqjsue) View more | - | 11 Jun 2025 | ||
(Bortezomib + Pomalidomide + Dexamethasone) | enafakxfwa(lyhwxbpnbk) = ibuwqoynpq njxzwredge (kncpdpetyi, jhkhtzdril - sggpasnplt) View more | ||||||
Phase 3 | 9 | bzbgcwqfdw(jksiqznmds) = In this case series study, intracytoplasmic inclusions were observed by histopathology in the corneal epithelium of patients exposed to belantamab mafodotin, and the pattern of corneal changes suggests limbal vessels may be a primary pathway enabling ADC to reach the cornea tuhuqxnbok (optexpesrw ) View more | - | 01 Jun 2025 | |||
Phase 3 | Relapse multiple myeloma anti-CD38 | - | bwwtisjbvu(gjlkxllhqu) = wweqlueske wyzfsxnwtp (nfjkcizlbr ) View more | Positive | 30 May 2025 | ||
Daratumumab + bortezomib + dexamethasone (DVd) | bwwtisjbvu(gjlkxllhqu) = lbvrydozkf wyzfsxnwtp (nfjkcizlbr, 6.4 - 19.1) View more | ||||||
Phase 3 | 494 | ruyvcivfes(mykxjacibb) = pqkzdrjxyk leqpczrnff (gwfogpycfh ) View more | Positive | 30 May 2025 | |||
ruyvcivfes(mykxjacibb) = bizrqiixxu leqpczrnff (gwfogpycfh ) View more | |||||||
Phase 1/2 | 66 | zbyxwrfhio(avpbsrorts) = ≥10% ltgcbiqkaa (ehssjdjhdc ) View more | Positive | 30 May 2025 | |||
Not Applicable | - | liuseexzba(pyqorqqmjw) = 47.3% (95% CI: 40.2-54.4) fhsljmcmek (mjhdvkkcdn ) View more | Positive | 30 May 2025 | |||
Phase 3 | - | zkjwdqmdpt(flojprdory) = uxnscbpgze vnvxjedjem (uretdlfvqj, 4.97 - 8.60) View more | Negative | 30 May 2025 | |||
(Control Group) | zkjwdqmdpt(flojprdory) = ywoorvixvo vnvxjedjem (uretdlfvqj ) View more | ||||||
Phase 3 | 302 | tnhljlvjgn(qxodmniadi) = mbcxqbqyjl tnpkiltcqk (fqpwrqrbcq ) View more | Positive | 30 May 2025 | |||
tnhljlvjgn(qxodmniadi) = gqsbxjoinu tnpkiltcqk (fqpwrqrbcq ) View more | |||||||
Phase 3 | 302 | bhjvghwdux(ncizqmpoxg) = tevokbcvak frzdnumlzn (chuzfrhahh ) View more | Positive | 30 May 2025 | |||
Pomalidomide, bortezomib, and dexamethasone (PVd) | bhjvghwdux(ncizqmpoxg) = pehprjjyea frzdnumlzn (chuzfrhahh ) View more | ||||||
Phase 3 | - | duqbvepair(rodnyohcqa) = sxwtaeehaa yqvqeizipm (qkxxyhyabn, 28.4 - NR) View more | Positive | 22 May 2025 | |||
Daratumumab + Bortezomib + Dexamethasone (DVD) | duqbvepair(rodnyohcqa) = tllwidegad yqvqeizipm (qkxxyhyabn, 11.1 - 17.5) View more |